ArticleFrontiers in cardiovascular medicine2026
Risk factors of coronary artery disease in metabolic-associated fatty liver disease: a single center cross-sectional study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and objectives: The specific risk factors contributing to coronary artery disease (CAD) in individuals with metabolic-associated fatty liver disease (MAFLD) have not been comprehensively examined. Given the critical role of inflammation in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), the monocyte to high-density lipoprotein cholesterol ratio (MHR) has emerged as a novel and significant inflammatory biomarker linked to CAD. Therefore, the primary objective of this study was to identify the risk factors associated with CAD in the MAFLD population, to analyze and compare MHR levels in MAFLD patients with and without concurrent CAD, and to evaluate the diagnostic and predictive value of MHR for CAD incidence within this high-risk cohort. Materials and methods: In total, 251 patients with MAFLD, comprising 151 individuals with CAD and 100 without CAD, were included in the study conducted at the First People's Hospital of Yangquan. The diagnosis of CAD was established through coronary angiography. Biochemical indices were collected and subjected to logistic regression analysis to identify markers that exhibited differential expression between MAFLD patients with CAD and those without CAD. These markers were subsequently integrated into a diagnostic model. The predictive efficacy of this model was evaluated using Decision Curve Analysis (DCA). Furthermore, the relationship between the MHR and other markers was examined using Spearman's correlation analysis. Results: Gender, age, white blood cell count (WBC), total cholesterol (TC), and the MHR were identified as significant risk factors for CAD in patients with MAFLD. Based on the area under the curve (AUC) value, the diagnostic model incorporating these five risk factors demonstrated robust diagnostic performance, with an AUC of 0.809. The DCA further validated its diagnostic effectiveness. Additionally, MHR was found to possess substantial diagnostic value for the occurrence of CAD events in MAFLD patients, with an AUC of 0.701. Further analysis of MHR quartiles revealed that patients in the highest quartile exhibited a significantly elevated risk of CAD compared to those in the other three quartiles. Moreover, significant correlations were observed between MHR and body mass index, WBC, uric acid, creatinine and triglycerides. Conclusion: The findings confirmed the importance of gender, age, WBC, TC, and MHR in predicting the occurrence of CAD in MAFLD populations, with MHR showing higher predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.